drugset / Trial / NCT01250210

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

NCT01250210

Phase 2 Completed 123 enrolled Agile Therapeutics
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluate the adequacy of ovulation suppression, cycle control, and safety of three transdermal contraceptive delivery systems (TCDSs).

Timeline

Start
2007-09
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule 2.17 mg
Subject Levonorgestrel Small molecule 2.6 mg
Subject ethinyl estradiol Small molecule 1.28 mg
Subject ethinyl estradiol Small molecule 1.92 mg
Subject ethinyl estradiol Small molecule 2.3 mg

Indications